Answers are grounded in this paper and cite their sources.
BACKGROUND AND AIMS: Macrovascular invasion (MaVI) defines advanced-stage hepatocellular carcinoma (HCC) and typically mandates systemic therapy, yet some guidelines advocate surgery or locoregional approaches. We conducted a systematic review and meta-analysis of overall survival (OS) in HCC with MaVI treated with approaches other than systemic therapy, enforcing stringent inclusion criteria to exclude studies lacking a minimal prognostic dataset and to improve cohort comparability. APPROACH AND RESULTS: PRISMA-guided methods were used (CRD420251051847). PubMed was searched (January 2008 to November 2024). Eligible studies reported OS for HCC with MaVI and provided baseline performance status and liver function; studies without adequate prognostic information were excluded. Data on OS at 1, 2, 3, and 5 years were extracted, and heterogeneity was assessed. Seventy-three studies met criteria (104 treatment arms; 10,329 patients). Despite a rigorous identification process, substantial heterogeneity persisted for most modalities ( I2 >80%), precluding robust pooling. Transarterial radioembolization (TARE) monotherapy was the only treatment with low heterogeneity ( I2 =0%) and showed a pooled 1-year OS of 34% (95% CI: 20%-48%). Apparent advantages of sequential strategies likely reflected confounding by indication and immortal-time bias, as only patients who lived long enough and were sufficiently fit proceeded through the full sequence. Data completeness declined beyond 12 months (missing OS: 0% at 1 y; 17.3% at 2 y; 32.7% at 3 y; 70.2% at 5 y). CONCLUSIONS: In HCC with MaVI, 1-year OS is the most comparable endpoint across modalities. This analysis identifies TARE as the only consistently reproducible option, showing a 1-year survival of 34%. In contrast, surgery and sequential therapies remain confounded by substantial heterogeneity. Accordingly, stratified head-to-head trials comparing alternative modalities against immunotherapy are warranted.
No takes yet. Share an insight, caveat, or question.
Fortuny et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: